Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology for mental health care and research in psychedelics, today announced that it has developed a number of non-racemic mixtures of ibogaine and has filed a provisional patent for these mixtures and their therapeutic use in treating a range of central nervous system (“CNS”) disorders. “MINDCURE is actively on course, further advancing our proprietary synthesis processes, and developing a series of mixtures from our fully synthetic ibogaine, serving as a key catalyst and important step in our pre-clinical development program towards Good Manufacturing Practice (‘GMP’) certification of ibogaine and the ability to scale and manufacture a global supply of fully synthetic ibogaine for research partners,” said MINDCURE’s CEO and President Kelsey Ramsden. “The filing of this additional provisional patent representing our novel ibogaine program (‘MC-808’) is another significant milestone within a comprehensive strategy that is fundamental to securing solid intellectual property protection and future commercial success.”
To view the full press release, visit https://ibn.fm/m9K1n
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.